Evidence map›Paper›PMID 28860764›Full record

ReviewInternational journal of nanomedicine2017

Liposomal curcumin and its application in cancer.

Ting Feng, Yumeng Wei, Robert J Lee, Ling Zhao

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers.

0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

165 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Chemical constituents in the rhizome of Curcuma longa and the pharmacological importance of curcumin hybrids.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. [Formation mechanisms, construction, and performance evaluation of self-assembled nanoparticles derived from natural products].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Curcumin Protected CoClFood science & nutrition · 2026
    Article
  19. Curcumin in Fibrosis Treatment: A Review.Drug design, development and therapy · 2026
    Review
  20. Review

105 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ting Feng *Department of Pharmaceutics, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
Yumeng Wei *Department of Pharmaceutics, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
Robert J LeeDivision of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Ling ZhaoDepartment of Pharmaceutics, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin (CUR) is a yellow polyphenolic compound derived from the plant turmeric. It is widely used to treat many types of diseases, including cancers such as those of lung, cervices, prostate, breast, bone and liver. However, its effectiveness has been limited due to poor aqueous solubility, low bioavailability and rapid metabolism and systemic elimination. To solve these problems, researchers have tried to explore novel drug delivery systems such as liposomes, solid dispersion, microemulsion, micelles, nanogels and dendrimers. Among these, liposomes have been the most extensively studied. Liposomal CUR formulation has greater growth inhibitory and pro-apoptotic effects on cancer cells. This review mainly focuses on the preparation of liposomes containing CUR and its use in cancer therapy.

Indexed as

Antineoplastic Agents, PhytogenicBiological AvailabilityCurcumaCurcuminDrug Delivery SystemsHumansLiposomesNanoparticlesNeoplasmsSolubilityAntineoplastic Agents, PhytogenicCurcuminLiposomesbioavailabilitycancercurcumindrug deliveryliposomes

Identifiers

PMID28860764
PMCPMC5573051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.